What Is HCG Therapy

HCG therapy for men involves the administration of human chorionic gonadotropin, a glycoprotein hormone that structurally and functionally mimics luteinizing hormone (LH). By binding to LH receptors on testicular Leydig cells, HCG stimulates endogenous testosterone production and supports spermatogenesis. It is used both as a standalone treatment for certain types of hypogonadism and as an adjunct to testosterone replacement therapy.

Testosterone production and male fertility both depend on signals from the pituitary gland, specifically LH and follicle-stimulating hormone (FSH). When exogenous testosterone is introduced through replacement therapy, the hypothalamic-pituitary-gonadal (HPG) axis detects elevated hormone levels and suppresses its own LH and FSH output. Without those signals, the testes shrink, intratesticular testosterone drops, and sperm production can cease. This creates a direct conflict for men who need testosterone support but also want to maintain fertility or testicular volume.

HCG addresses this conflict by acting as a substitute for the body's suppressed LH. By keeping the Leydig cells active, HCG preserves the local testosterone environment the testes need for sperm maturation. For men with secondary hypogonadism, where the deficiency originates from insufficient pituitary signaling rather than testicular failure, HCG can sometimes restore testosterone levels without introducing exogenous testosterone at all. This distinction matters for long-term reproductive planning and for avoiding the complete shutdown of the HPG axis that accompanies standard TRT.

Human chorionic gonadotropin shares a common alpha subunit with LH and binds the same LH/CG receptor on Leydig cells. Once bound, it activates a cyclic AMP signaling cascade that upregulates the enzymatic machinery responsible for converting cholesterol into testosterone. The key enzymes in this pathway include steroidogenic acute regulatory protein (StAR), which transports cholesterol into the mitochondria, and cytochrome P450 enzymes that catalyze the sequential conversions through pregnenolone, DHEA, androstenedione, and finally testosterone.

Intratesticular testosterone concentrations are normally 50 to 100 times higher than serum levels. This gradient is critical because Sertoli cells, which nurse developing sperm through maturation, require high local testosterone to function properly. When exogenous TRT suppresses LH, intratesticular testosterone can fall to levels too low for spermatogenesis even if serum testosterone appears normal. HCG restores this intratesticular concentration, which is why it supports sperm production in ways that exogenous testosterone alone cannot.

Because HCG stimulates the same pathway that produces testosterone, it also drives downstream metabolites. Some of the testosterone produced under HCG stimulation is aromatized to estradiol by the enzyme aromatase, which is present in fat tissue, the testes, and other organs. This is why estradiol monitoring is a standard part of HCG therapy protocols. The half-life of HCG is roughly 24 to 36 hours, which supports dosing schedules of two to three injections per week for sustained Leydig cell stimulation.

Male testosterone production is governed by a tightly regulated feedback loop. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in a pulsatile pattern, which stimulates the anterior pituitary to secrete LH and FSH. LH acts on Leydig cells to produce testosterone, while FSH acts on Sertoli cells to support spermatogenesis. Rising testosterone feeds back to the hypothalamus and pituitary, reducing GnRH, LH, and FSH output.

When exogenous testosterone enters the system through TRT, the hypothalamus interprets it as a signal that testosterone is sufficient and reduces GnRH output. The result is suppressed LH and FSH, which leads to reduced intratesticular testosterone and compromised sperm production. HCG sidesteps this suppression by acting directly at the Leydig cell, independent of the pituitary. It essentially replaces the missing LH signal, keeping the downstream steroidogenic machinery active even when the upstream pituitary output has been shut down.

The hormonal context also includes estradiol management. Testosterone produced under HCG stimulation is subject to aromatization, and some men on HCG experience a disproportionate rise in estradiol relative to testosterone. This is influenced by body fat percentage, aromatase enzyme polymorphisms, and total hormone load. Monitoring the testosterone-to-estradiol ratio, rather than either hormone in isolation, provides a more complete picture of the hormonal environment.

Men who may benefit from HCG therapy often present with symptoms of low testosterone: reduced libido, fatigue, depressed mood, difficulty building or maintaining muscle mass, cognitive sluggishness, and diminished morning erections. When these symptoms coincide with low or low-normal serum testosterone and low or inappropriately normal LH, the pattern suggests secondary hypogonadism, which is the clinical scenario most responsive to HCG.

For men already on TRT, the signals that HCG may be needed include testicular shrinkage (which many men notice as a decrease in size and firmness), reduced ejaculate volume, and concern about future fertility. Testicular atrophy on TRT is not merely cosmetic; it reflects the functional shutdown of Leydig and Sertoli cells. Some men also report a subjective difference in well-being when intratesticular testosterone is maintained via HCG versus when it is not, though this observation lacks controlled study.

Signs that HCG dosing may need adjustment include nipple tenderness, bloating, mood swings, or acne, which often indicate excessive estradiol conversion. Conversely, if testosterone levels fail to rise adequately on HCG monotherapy, it may indicate primary testicular insufficiency rather than a pituitary problem, which changes the treatment approach.

HCG is most commonly used in two clinical contexts for men. The first is as an adjunct to TRT, where it is co-administered to preserve testicular size and fertility. Standard adjunctive protocols typically use 250 to 500 IU subcutaneously two to three times per week, timed to maintain consistent Leydig cell stimulation. Some clinicians dose on the same days as testosterone injections; others stagger the timing to smooth hormonal fluctuations.

The second context is HCG monotherapy for men with secondary hypogonadism who wish to avoid exogenous testosterone entirely. This approach relies on the testes' remaining capacity to produce testosterone when adequately stimulated. Monotherapy doses are often higher, ranging from 1,000 to 2,000 IU two to three times weekly, and may be combined with an aromatase inhibitor if estradiol rises disproportionately. Monotherapy is less likely to succeed in men with primary testicular failure, where the Leydig cells themselves are compromised.

A third, less common application is as a "restart" protocol after discontinuing TRT, where HCG is used for several weeks to reactivate the testes before tapering off, sometimes in combination with selective estrogen receptor modulators such as clomiphene or enclomiphene. The goal is to bridge the gap between exogenous testosterone withdrawal and the recovery of endogenous HPG axis function. Protocol details vary widely among practitioners, and the evidence base for optimal restart strategies remains limited to case series and clinical experience rather than large trials.

Clinical evidence for HCG use in men comes primarily from reproductive endocrinology and urology literature. Multiple observational studies and small clinical trials have demonstrated that HCG co-administered with TRT can maintain spermatogenesis and testicular volume in men who would otherwise experience both losses. Studies in men with hypogonadotropic hypogonadism (secondary hypogonadism) show that HCG monotherapy can raise serum testosterone into the normal range and restore fertility, particularly when combined with FSH in cases of more severe gonadotropin deficiency.

Large-scale randomized controlled trials specifically comparing HCG protocols in the context of TRT are limited. Much of the clinical practice around dosing and frequency is guided by expert consensus, case series, and extrapolation from fertility medicine. The American Urological Association guidelines acknowledge HCG as a tool for fertility preservation during testosterone therapy, though they note that long-term safety data in the specific context of prolonged adjunctive use alongside TRT remain sparse. The FDA-approved indications for HCG in men are limited to certain cases of hypogonadism and cryptorchidism, and many clinical uses in the longevity and hormone optimization space are considered off-label.

HCG can increase estradiol levels, potentially causing gynecomastia, water retention, mood instability, and elevated hematocrit. Desensitization of Leydig cell LH receptors is a theoretical concern with prolonged high-dose use, though clinically significant desensitization at standard doses appears uncommon. HCG is a controlled substance in some jurisdictions, and pharmaceutical-grade product availability has fluctuated due to regulatory changes affecting compounding pharmacies. Men with hormone-sensitive conditions such as prostate cancer should not use HCG without careful oncological evaluation. All HCG use should be supervised by a clinician who monitors bloodwork and adjusts therapy based on individual response.